Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients
Focus:
-
![dexamethasone]()
Dexamethasone, an unexpected drug, shows promise in treating Covid-19
-
![covid-19 vaccines]()
CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster
-
![europe covid-19 clinical trials]()
The UK leads Covid-19 clinical investigations in Europe
-
![Clinical trial risk management]()
Dealing with the unexpected: Covid-19 and risk management
-
![relugolix trial]()
Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive
-
![astrazenecas tagrisso]()
AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer
Most Read
- Exploring efficiencies from eTMF with Cancer Research UK
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
Company A-Z
Latest Content
VITAPLAN PLUS
VITAPLAN PLUS provides a selection of amino acids, vitamins and dry plant extracts in consistent quantities with the effectiveness demonstrated by scientific evidence to provide an ideal setting for your sex.
IQVIA and LMC Manna Research to launch Prime Site in Canada
IQVIA has entered a strategic alliance with LMC Manna Research to launch its first Prime Site for clinical investigation in Canada.
Trials Delayed Due to Covid-19 Begin to Resume
Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the COVID-19 pandemic.
2020 Forthcoming Events
Below are the forthcoming shows that will exhibit Malvern’s pharmaceutical solutions.
Patented Extracts, Amino Acids and Enzymes for Manufacturing Natural Plant-Based Products
Our best own brand product selection to the highest quality plant extracts.
Dealing with the unexpected: Covid-19 and risk management
Major global events such as the ongoing Covid-19 pandemic can cause significant problems for clinical trials and pharma research programmes. Oncoinvent head of clinical operations Helén Johansen Blanco shares her expertise on proactive risk management and when a risk becomes an issue.
Latest News
Close
Close
Close
Go Top